medigraphic.com
ISSN 1729-519X (Print)

2022, Number 2

<< Back Next >>

Revista Habanera de Ciencias Médicas 2022; 21 (2)

Prophylactic use of nasalferon against COVID-19 in healthcare workers. Early surveillance study

Hernández PJC, Planas SN, Portela CS, Peña GYE, Abdo CAA, Castellanos GR, Guerrero CMC, Piñeiro PD, Tuero IÁD

Language: Spanish
References: 40
Page:
PDF size: 666.64 Kb.


ABSTRACT

Introduction: In Cuba, the nasal application of recombinant human IFN-alpha- 2b (nasalferon) began in personnel at risk in order to prevent SARS-CoV-2 infection.
Objective: To characterize the safety in those subjects exposed to the use of Nasalferon at the Surgical Medical Research Center and to explore the effect of the prophylactic use of the drug against acute respiratory symptoms mainly caused by SARS-CoV-2.
Material and Methods: Monocentric, prospective, open, and early surveillance epidemiological study conducted in healthcare workers who were administered Nasalferon. Surveillance was performed using the Prescription-Related Adverse Event Monitoring Surveillance method. The main variable was the presence of adverse events. Secondarily, the effect of the drug in preventing virus infection was explored. For the analysis of the main variable, the proportion of subjects who experienced each of the adverse events was estimated. In addition, the frequency distribution of the type of event, intensity, severity, and causality or imputability were estimated.
Results: A total of 86 subjects were included; 50 of them experienced 15 types of adverse events. No severe or serious events were reported. Headache, leukopenia, decay, and arterial hypertension were classified as moderate ones. During the whole duration of the treatment and until a month after it, none of the subjects included in the study presented COVID-19 or other viral acute respiratory symptoms.
Conclusions: Nasalferon proved to be a safe and tolerable drug and the included subjects did not present acute respiratory symptoms related or unrelated to COVID-19.


REFERENCES

  1. WHO. COVID-19 UPDATE [Internet]. Switzerland: WHO; 2022 [Citado 16/03/2022]. Disponible en: Disponible en: https://www.unmultimedia.org/tv/unifeed/asset/2715/2715557 1.

  2. MINSAP. Nota informativa sobre el nuevo coronavirus en Cuba [Internet]. La Habana: Ministerio de Salud Pública de Cuba; 2020 [Citado 17/12/2021]. Disponible en: Disponible en: https://salud.msp.gob.cu/nota-informativa-sobre-el-nuevo-coronavirus-en-cuba/ 2.

  3. MINSAP. Parte de cierre del día 16 de diciembre a las 12 de la noche [Internet]. La Habana: Ministerio de Salud Pública de Cuba; 2021 [Citado 17/12/2021]. Disponible en: Disponible en: https://salud.msp.gob.cu/parte-de-cierre-del-dia-16-de-diciembre-a-las-12-de-la-noche-2/ 3.

  4. Martínez Díaz E, Pérez Rodríguez R, Herrera Martínez L, Lage Dávila A, Castellanos Serra L. La industria biofarmacéutica cubana en el combate contra la pandemia de COVID-19. An Acad Cienc Cuba [Internet]. 2020 Aug [Citado 17/12/2021];10(2):12. Disponible en: Disponible en: http://www.revistaccuba.cu/index.php/revacc/article/view/906 4.

  5. Stetson DB, Medzhitov R. Type I Interferons in Host Defense. Immunity [Internet]. 2006;25(3):373-81. Disponible en: http://doi.org/10.1016/j.immuni.2006.08.007

  6. Qian G, Zhu L, Li G, Liu Y, Zhang Z, Pan J, et al. An Integrated View of Deubiquitinating Enzymes Involved in Type I Interferon Signaling, Host Defense and Antiviral Activities. Front Immunol [Internet]. 2021;12:4110. Disponible en: http://doi.org/10.3389/fimmu.2021.742542

  7. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani Alvarez L, Polacco B, Pelin A, et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature [Internet]. 2021;602:487-95. Disponible en: http://doi.org/10.1038/s41586-021-04352-y

  8. Chen X, Saccon E, Appelberg KS, Mikaeloff F, Rodriguez JE, Vinhas BS, et al. Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells. Cell Death Discov [Internet]. 2021;7(1):1-15. Disponible en: http://doi.org/10.1038/s41420-021-00487-z

  9. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science [Internet]. 2020;369:718-24. Disponible en: http://doi.org/10.1126/science.abc6027

  10. Blanco Melo D, Nilsson Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell [Internet]. 2020;181(5):1036-1045.e9. Disponible en: http://doi.org/10.1016/j.cell.2020.04.026

  11. Batista Dos Santos JM, Pereira Soares C, Rodrigues Monteiro F, Mello R, do Amaral J, Simões Aguiar A, et al. In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 Infection. Front Immunol [Internet]. 2021;12:595343. Disponible en: http://doi.org/10.3389/fimmu.2021.595343

  12. Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother [Internet]. 1983;24(5):713-5. Disponible en: http://doi.org/10.1128/AAC.24.5.713

  13. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon. J Infect Dis [Internet]. 1986;154(3):443-7. Disponible en: http://doi.org/10.1093/infdis/154.3.443

  14. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA [Internet]. 2003;290(24):3222-8. Disponible en: http://doi.org/10.1001/jama.290.24.3222

  15. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis [Internet]. 2014;14(11):1090-5. Disponible en: http://doi.org/10.1016/S1473-3099(14)70920-X15.

  16. Strayer DR, Dickey R, Carter WA. Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans. Infect Disord - Drug Targets [Internet]. 2014;14(1):37-43. Disponible en: http://doi.org/10.2174/1871526514666140713152858

  17. Ziegler CGK, Allon SJ, Nyquist SK, Mbano IM, Miao VN, Tzouanas CN, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell [Internet]. 2020;181(5):1016-1035.e19. Disponible en: http://doi.org/10.1016/j.cell.2020.04.035

  18. Gao L, Yu S, Chen Q, Duan Z, Zhou J, Mao C, et al. A randomized controlled trial of low-dose recombinant human interferons α-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine [Internet]. 2010;28(28):4445-51. Disponible en: http://doi.org/10.1016/j.vaccine.2010.03.062

  19. Tannock GA, Gillett SM, Gillett RS, Barry RD, Hensley MJ, Herd R, et al. A study of intranasally administered interferon A* (rIFN-α2A) for the seasonal prophylaxis of natural viral infections of the upper respiratory tract in healthy volunteers. Epidemiol Infect [Internet]. 1988;101(3):611-21. Disponible en: http://doi.org/10.1017/S0950268800029484

  20. Higgins PG, Barrow GI, Tyrrell DAJ, Isaacs D, Gauci CL. The efficacy of intranasal interferonα-2a in respiratory syncytial virus infection in volunteers. Antiviral Res [Internet]. 1990;14(1):3-10. Disponible en: http://doi.org/10.1016/0166-3542(90)90061-B

  21. Douglas RM, Moore BW, Miles HB, Davies LM, Graham NM, Ryan P, et al. Prophylactic efficacy of intranasal alpha 2-interferon against rhinovirus infections in the family setting. N Engl J Med [Internet]. 1986 Jan 9;314(2):65-70. Disponible en: http://doi.org/10.1056/NEJM198601093140201

  22. Lee AC, Jeong Y, Lee S, Jang H, Zheng A, Kwon S, et al. Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections. Front Immunol [Internet]. 2021;12:1927. Disponible en: http://doi.org/10.3389/fimmu.2021.660298

  23. Higgins TS, Wu AW, Illing EA, Sokoloski KJ, Weaver BA, Anthony BP, et al. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review. Otolaryngol Neck Surg [Internet]. 2021;163(4):682-94. Disponible en: http://doi.org/10.1177/0194599820933170

  24. Pereda R, González D, Rivero HB, Rivero JC, Pérez A, López LDR, et al. Therapeutic Effectiveness of Interferon-α2b Against COVID-19: The Cuban Experience. J Interferon Cytokine Res [Internet]. 2020;40(9):438-42. Disponible en: http://doi.org/10.1089/jir.2020.0124

  25. Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area. Curr Top Med Chem [Internet]. 2021;21(10):920-7. Disponible en: http://doi.org/10.2174/156802662166621042908305025.

  26. Organización Mundial de la Salud. Actualización de la estrategia frente a la COVID-19 [Internet]. Ginebra: OMS; 2020 [Citado 20/12/2021]. Disponible en: Disponible en: https://www.who.int/docs/default-source/coronaviruse/covid-strategy-update-14april2020_es.pdf 26.

  27. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos. NASALFERON (Interferón alfa 2b humano recombinante) | CECMED [Internet]. La Habana: CECMED; 2021. [Citado 28/12/2021]. Disponible en: Disponible en: https://www.cecmed.cu/registro/rcp/biologicos/nasalferon-interferon-alfa-2b-humano-recombinante 27.

  28. MINSAP. Protocolo de actuación nacional contra la COVID-19. Versión 2.1 [Internet]. La Habana: MINSAP; 2020 [Citado 20/12/2021]. Disponible en: Disponible en: https://covid19cubadata.github.io/protocolos/protocolo-version-2.pdf 28.

  29. WHO Collaborating Centre for International Drug Monitoring. International monitoring of adverse reactions to drugs : Adverse Reaction Terminology [Internet]. Uppsala: WHO Collaborating Centre for International Drug Monitoring; 1992 [Citado 20/12/2021]. Disponible en: Disponible en: https://apps.who.int/iris/handle/10665/61056 29.

  30. Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment [Internet]. Uppsala: Uppsala Monitoring Centre; 2018 [Citado 20/12/2021]. Disponible en: Disponible en: https://who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf 30.

  31. Shakir SAW. Prescription-Event Monitoring. In: Strom BL, ed. Pharmacoepidemiology [Internet]. England: John Wiley & Sons, Ltd; 2006.p. 203-16 [Citado 20/12/2021]. Disponible en: Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470059876.ch12 31.

  32. Cañete R, León LM, Rodríguez L. An Experience with Cuban Biotech’s Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts. MEDICC Rev [Internet]. 2021;23(2):10. Disponible en: http://doi.org/10.37757/MR2021.V23.N2.1

  33. Abdo Cuza A, Castellanos Gutiérrez R, Treto Ramirez J, Arencibia Larin S, Gómez Pariente T, González Fernández T, et al. Safety and efficacy of intranasal recombinant human interferon alfa 2b as prophylaxis for COVID-19 in patients on a hemodialysis program. J Ren Endocrinol [Internet]. 2020;7(1):e05-e05. Disponible en: http://doi.org/10.34172/jre.2021.05

  34. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract Res Clin Gastroenterol [Internet]. 2010;24(2):183-92. Disponible en: http://doi.org/10.1016/j.bpg.2009.10.012

  35. Scott GM, Onwubalili JK, Robinson JA, Doré C, Secher DS, Cantell K. Tolerance of one-month intranasal interferon. J Med Virol [Internet]. 1985;17(2):99-106. Disponible en: http://doi.org/10.1002/jmv.1890170202

  36. Khanna NR, Gerriets V. Interferon [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [Citado 22/12/2021]. Disponible en: Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK555932/ 36.

  37. Sleijfer S, Bannink M, Van Gool AR, Kruit WHJ, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci [Internet]. 2005;27(6):423. Disponible en: http://doi.org/10.1007/s11096-005-1319-737.

  38. Dusheiko G. Side effects of α interferon in chronic hepatitis C. Hepatology [Internet]. 1997;26(S3):112S-121S. Disponible en: http://doi.org/10.1002/hep.510260720

  39. Spiegel RJ. Clinical overview of alpha interferon. Studies and future directions. Cancer [Internet]. 1987;59(S3):626-32. Disponible en: http://doi.org/10.1002/1097-0142(19870201)59:3+<626::AID-CNCR2820591310>3.0.CO;2-D

  40. Weiss K. Safety profile of interferon-alpha therapy. Semin Oncol. 1998 Feb;25(1 Suppl):9-13.




2020     |     www.medigraphic.com